MIDN

Across TCGA pan-cancer cohorts, MIDN Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MIDN data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher MIDN Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIDN expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

OV, UCEC, and SKCM are the cancer types where MIDN Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.022	0.844	<.001	48	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.359	0.788	.007	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.412	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MIDN–OV (OS)

Open the OV breakdown →